UroGen Pharma Ltd

Healthcare · Biotechnology

42.80$ +3.3% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

UroGen Pharma Ltd (URGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 253 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet URGN
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	9.4	23	–	79	81	76	129	122	113	104	252	239	227	202	167	161	140	122	97	154	135	120	166	146	128	136	113	95	194	178	201	282	302	286	248	209	185	200	254	253
Current Assets	8.6	22	21	78	80	74	129	121	111	102	248	191	160	149	122	130	129	116	93	140	125	114	161	140	122	129	96	81	182	169	197	279	295	276	237	197	169	186	237	235
Cash	8.2	21	-21	77	79	37	127	119	109	101	247	90	66	50	26	36	25	53	40	63	55	44	105	81	29	55	37	20	119	96	132	220	125	172	104	93	90	111	111	79
Cash & Short-Term Investments	8.2	21	21	77	79	73	127	119	109	101	247	189	158	147	119	125	120	102	76	121	106	89	136	112	96	100	65	47	147	138	165	241	250	237	196	157	127	120	142	108
Receivables	–	0.1	–	0.0	0.0	0.2	0.0	0.2	0.1	–	–	–	–	–	–	0.4	2.8	7.0	6.3	9.5	7.8	12	9.5	12	9.4	13	12	16	13	15	14	17	23	20	20	20	20	33	55	89
Inventory	–	0.1	–	0.4	0.1	0.3	0.3	0.1	0.2	–	–	–	–	–	–	1.1	1.3	2.0	3.3	3.4	3.8	4.8	4.8	5.0	4.9	4.3	5.5	5.0	5.0	5.7	7.2	7.4	7.6	9.2	7.6	7.1	8.3	16	21	25
Property, Plant & Equipment	–	0.7	–	0.7	0.7	0.8	0.6	0.7	1.0	0.9	3.7	3.5	3.3	4.7	4.4	4.4	1.7	4.2	2.1	3.7	2.0	2.0	1.8	1.6	4.2	1.3	1.1	0.9	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	4.0	6.7	–	5.0	4.9	7.0	5.5	8.0	9.0	13	12	14	16	22	16	18	19	26	21	97	103	111	183	187	192	225	230	234	236	244	241	252	276	295	294	302	300	306	378	385
Current Liabilities	4.0	3.1	–	5.0	4.9	7.0	5.5	8.0	9.0	13	10	12	14	19	14	16	18	21	17	19	20	22	19	18	19	24	25	27	26	31	26	34	33	46	42	48	42	46	51	62
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	1.0	1.1	1.1	–	1.6	1.5	1.3	–	1.7	1.1	1.1	3.3	0.9	0.8	0.9	0.9	0.9	0.9	0.9	0.8	0.8	1.6	0.8	3.1	1.4	1.5	1.6	–	1.9	2.1
Accounts Payable	2.8	1.9	–	3.5	3.5	2.8	4.0	5.7	6.3	4.3	1.7	2.1	2.6	4.7	4.2	4.6	4.1	3.3	6.1	4.8	4.1	5.8	4.2	2.5	2.5	5.5	7.0	4.7	4.0	6.5	6.3	8.3	5.6	11	15	14	10	12	17	40
Long-Term Debt	–	3.6	–	–	–	–	–	–	–	–	2.2	–	–	–	–	–	–	–	–	–	–	–	71	71	72	98	98	98	99	99	98	98	122	122	122	123	122	122	190	189
Shareholders' Equity	5.4	16	20	74	76	69	124	114	104	90	240	225	211	180	150	143	121	96	76	56	32	8.4	-17	-41	-63	-89	-117	-138	-42	-65	-40	30	26	-8.8	-46	-93	-115	-105	-124	-132
Retained Earnings	-40	-27	–	-37	-37	-47	-61	-79	-99	-123	-144	-167	-189	-228	-266	-297	-326	-357	-382	-409	-439	-467	-496	-522	-548	-577	-607	-631	-653	-679	-712	-745	-769	-806	-850	-900	-933	-960	-983	-998
Shares Outstanding	12	11	11	9.2	13	14	15	16	16	16	19	21	21	21	21	22	22	22	22	22	22	22	23	23	23	23	23	23	32	36	33	37	43	47	47	48	48	49	50	50

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings